Dr. Guillaume Churlaud and his team produce cell and gene therapies, such as mesenchymal stromal cells, Treg lymphocytes, CAR-T cells, NK cells, and other ATMPs. All ATMPs produced in the MEARY Center are for phase 1 and 2 clinical trials. They produce new cells and new gene therapy drugs to treat patients suffering from autoimmune, hematological, and cardiac diseases, and so much more.
MEARY Center is the Paris University Hospitals Consortium’s core facility for cell and gene therapy. It is dedicated to the manufacturing of Advanced Therapy Medicinal Products (ATMPs) for the 39 leading university hospitals belonging to AP-HP (www.centremeary.aphp.fr). Located at the heart of Paris within Saint-Louis Hospital, it is embedded in an ecosystem connecting patients, research, and therapeutic innovation. The MEARY Center is accessible to diverse collaborators such as academic, biotech, and pharma companies.
Dr. Guillaume Churlaud, Senior Quality Control, Meary Institute at Saint-Louis Hospital, Paris, France, is the pharmacist in charge of the quality control laboratory within the Meary Center. He has been trained in the field on biotherapies in Paris hospitals, and has completed his training in the Clinical Investigation Center for Biotherapies at the Pitié Salpêtrière Hospital in Paris. He has more than ten years of experience in the development and quality control of hematopoietic stem cells and advanced therapy medicinal products. He also holds a Ph.D. in immunology, and has a strong expertise in basic and translational research in cell and gene therapy.
Watch the video of the interview with Dr. Guillaume Churlaud or read the transcript below.